HEK293 |
Function assay |
|
|
|
Glycogen synthase activity of HEK293 cells, inhibition of GSK3-beta, EC50=0.2μM |
12941331 |
HEK293 |
Function assay |
|
|
|
Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cells, EC50=0.2μM |
15149684 |
MIAPaCa2 |
Growth inhibition assay |
|
72 hrs |
|
Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay, IC50=25μM |
19338355 |
ST14A |
Function assay |
|
6 hrs |
|
Inhibition of GSK-3-beta-mediated Wnt signaling in human ST14A cells assessed as increase in accumulation of beta-casein around nucleus after 6 hrs by microscopic analysis |
20708937 |
neural precursor cells |
Function assay |
|
|
|
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
17417631 |
ReNcell VM |
Antiproliferative assay |
3 uM |
72 hrs |
|
Antiproliferative activity against human ReNcell VM cells assessed as reduction of cell proliferation at 3 uM after 72 hrs |
20708937 |
HepG2 |
Function assay |
34 uM |
12 hrs |
|
Increase in glucose incorporation in human HepG2 cells at 34 uM after 12 hrs by glucose assay |
25467150 |
3T3L1 |
Function assay |
34 uM |
12 hrs |
|
Increase in glucose incorporation in mouse 3T3L1 cells at 34 uM after 12 hrs by glucose assay |
25467150 |
HepG2 |
Function assay |
34 uM |
12 hrs |
|
Inhibition of GSK3beta in human HepG2 cells assessed as decrease in ratio of phosphorylated GS/GS at 34 uM after 12 hrs by Western blot analysis |
25467150 |
Sf9 |
Function assay |
|
30 min |
|
Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation counting, IC50=0.03388μM |
SANGER |
human HDLM-2 cell |
Growth inhibition assay |
|
|
|
Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50=0.20984 μM |
SANGER |
human NCI-H1770 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1770 cell growth in a cell viability assay. IC50=0.29392 μM |
SANGER |
human HOP-62 cell |
Growth inhibition assay |
|
|
|
Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=0.85256 μM |
SANGER |
human JAR cell |
Growth inhibition assay |
|
|
|
Inhibition of human JAR cell growth in a cell viability assay, IC50=1.21044 μM |
SANGER |
human K5 cell |
Growth inhibition assay |
|
|
|
Inhibition of human K5 cell growth in a cell viability, IC50=1.53698 μM |
SANGER |
human MV-4-11 cell |
Growth inhibition assay |
|
|
|
Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=2.69685 μM |
SANGER |
human BT-549 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BT-549 cell growth in a cell viability assay, IC50=5.29376 μM |
SANGER |
human LB2241-RCC cell |
Growth inhibition assay |
|
|
|
Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=6.42874 μM |
SANGER |
human GAMG cell |
Growth inhibition assay |
|
|
|
Inhibition of human GAMG cell growth in a cell viability assay, IC50=6.65409 μM |
SANGER |
human HMV-II cell |
Growth inhibition assay |
|
|
|
Inhibition of human HMV-II cell growth in a cell viability assay, IC50=7.67607 μM |
SANGER |
human RS4-11 cell |
Growth inhibition assay |
|
|
|
Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=8.24141 μM |
SANGER |
human NCI-H1993 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50=8.36534 μM |
SANGER |
human IST-SL1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=9.0204 μM |
SANGER |
human SK-OV-3 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=9.1002 μM |
SANGER |
human ESS-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=9.59872 μM |
SANGER |
human G-361 cell |
Growth inhibition assay |
|
|
|
Inhibition of human G-361 cell growth in a cell viability assay, IC50=10.1798 μM |
SANGER |
human ALL-PO cell |
Growth inhibition assay |
|
|
|
Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=10.3477 μM |
SANGER |
human NB5 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NB5 cell growth in a cell viability assay, IC50=11.2157 μM |
SANGER |
human DU-145 cell |
Growth inhibition assay |
|
|
|
Inhibition of human DU-145 cell growth in a cell viability assay, IC50=11.6535 μM |
SANGER |
human NMC-G1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=11.7264 μM |
SANGER |
human RPMI-7951 cell |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-7951 cell growth in a cell viability assay. IC50=11.7864 μM |
SANGER |
human NCI-H2009 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=13.2427 μM |
SANGER |
human LoVo cell |
Growth inhibition assay |
|
|
|
Inhibition of human LoVo cell growth in a cell viability assay, IC50=13.3771 μM |
SANGER |
human A2058 cell |
Growth inhibition assay |
|
|
|
Inhibition of human A2058 cell growth in a cell viability assay, IC50=13.469 μM |
SANGER |
human D-566MG cell |
Growth inhibition assay |
|
|
|
Inhibition of human D-566MG cell growth in a cell viability assay, IC50=13.9481 μM |
SANGER |
human QIMR-WIL cell |
Growth inhibition assay |
|
|
|
Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=15.6394 μM |
SANGER |
human S-117 cell |
Growth inhibition assay |
|
|
|
Inhibition of human S-117 cell growth in a cell viability assay, IC50=16.4022 μM |
SANGER |
human YH-13 cell |
Growth inhibition assay |
|
|
|
Inhibition of human YH-13 cell growth in a cell viability assay, IC50=16.6865 μM |
SANGER |
human IGROV-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=17.2001 μM |
SANGER |
human BHT-101 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BHT-101 cell growth in a cell viability assay, IC50=17.6099 μM |
SANGER |
human MKN45 cell |
Growth inhibition assay |
|
|
|
Inhibition of human MKN45 cell growth in a cell viability assay, IC50=18.4128 μM |
SANGER |
human A498 cell |
Growth inhibition assay |
|
|
|
Inhibition of human A498 cell growth in a cell viability assay, IC50=19.4549 μM |
SANGER |
human U-266 cell |
Growth inhibition assay |
|
|
|
Inhibition of human U-266 cell growth in a cell viability assay, IC50=20.8797 μM |
SANGER |
human BFTC-905 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=21.1879 μM |
SANGER |
human BxPC-3 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=21.3554 μM |
SANGER |
human NCI-SNU-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=21.5558 μM |
SANGER |
human SF539 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SF539 cell growth in a cell viability assay, IC50=22.0198 μM |
SANGER |
human VA-ES-BJ cell |
Growth inhibition assay |
|
|
|
Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=22.5763 μM |
SANGER |
human HuO-3N1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=22.6151 μM |
SANGER |
human EM-2 cell |
Growth inhibition assay |
|
|
|
Inhibition of human EM-2 cell growth in a cell viability assay, IC50=22.6689 μM |
SANGER |
human T98G cell |
Growth inhibition assay |
|
|
|
Inhibition of human T98G cell growth in a cell viability assay, IC50=23.3009 μM |
SANGER |
human SW1783 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SW1783 cell growth in a cell viability assay, IC50=23.5243 μM |
SANGER |
human NKM-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=23.8512 μM |
SANGER |
human KOSC-2 cell |
Growth inhibition assay |
|
|
|
Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50=24.1292 μM |
SANGER |
human SW48 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6067 μM |
SANGER |
human NCI-H28 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50=25.2104 μM |
SANGER |
human 5637 cell |
Growth inhibition assay |
|
|
|
Inhibition of human 5637 cell growth in a cell viability assay, IC50=25.8111 μM |
SANGER |
human NB69 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NB69 cell growth in a cell viability assay, IC50=26.1764 μM |
SANGER |
human HT-29 cell |
Growth inhibition assay |
|
|
|
Inhibition of human HT-29 cell growth in a cell viability assay, IC50=27.1752 μM |
SANGER |
human PFSK-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50=27.593 μM |
SANGER |
human UACC-257 cell |
Growth inhibition assay |
|
|
|
Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=27.743 μM |
SANGER |
human D-423MG cell |
Growth inhibition assay |
|
|
|
Inhibition of human D-423MG cell growth in a cell viability assay, IC50=27.9106 μM |
SANGER |
human NH-12 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NH-12 cell growth in a cell viability assay, IC50=28.4059 μM |
SANGER |
human DEL cell |
Growth inhibition assay |
|
|
|
Inhibition of human DEL cell growth in a cell viability assay, IC50=29.0474 μM |
SANGER |
human LS-513 cell |
Growth inhibition assay |
|
|
|
Inhibition of human LS-513 cell growth in a cell viability assay, IC50=30.1334 μM |
SANGER |
human NBsusSR cell |
Growth inhibition assay |
|
|
|
Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=30.5678 μM |
SANGER |
human BV-173 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BV-173 cell growth in a cell viability assay, IC50=30.7649 μM |
SANGER |
human A101D cell |
Growth inhibition assay |
|
|
|
Inhibition of human A101D cell growth in a cell viability assay, IC50=30.9784 μM |
SANGER |
human LU-134-A cell |
Growth inhibition assay |
|
|
|
Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=31.0238 μM |
SANGER |
human ES3 cell |
Growth inhibition assay |
|
|
|
Inhibition of human ES3 cell growth in a cell viability assay, IC50=31.3376 μM |
SANGER |
human NY cell |
Growth inhibition assay |
|
|
|
Inhibition of human NY cell growth in a cell viability assay, IC50=32.2965 μM |
SANGER |
human NCI-H1975 cell |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1975 cell growth in a cell viability assay, IC50=32.3582 μM |
SANGER |
human A704 cell |
Growth inhibition assay |
|
|
|
Inhibition of human A704 cell growth in a cell viability assay, IC50=34.2059 μM |
SANGER |
human SK-MEL-24 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=34.2523 μM |
SANGER |
human SW1088 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SW1088 cell growth in a cell viability assay, IC50=34.3452 μM |
SANGER |
human SK-MEL-1 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MEL-1 cell growth in a cell viability, IC50=34.714 μM |
SANGER |
human MOLT-4 cell |
Growth inhibition assay |
|
|
|
Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=36.1467 μM |
SANGER |
human T47D cell |
Growth inhibition assay |
|
|
|
Inhibition of human T47D cell growth in a cell viability assay, IC50=37.1647 μM |
SANGER |
human SW1710 cell |
Growth inhibition assay |
|
|
|
Inhibition of human SW1710 cell growth in a cell viability assay, IC50=37.3608 μM |
SANGER |
human MKN7 cell |
Growth inhibition assay |
|
|
|
Inhibition of human MKN7 cell growth in a cell viability assay, IC50=38.0909 μM |
SANGER |
human CAL-72 cell |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=38.1178 μM |
SANGER |
human AGS cell |
Growth inhibition assay |
|
|
|
Inhibition of human AGS cell growth in a cell viability assay, IC50=38.2039 μM |
SANGER |
human BE-13 cell |
Growth inhibition assay |
|
|
|
Inhibition of human BE-13 cell growth in a cell viability assay, IC50=38.7783 μM |
SANGER |
human Calu-6 cell |
Growth inhibition assay |
|
|
|
Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=39.6964 μM |
SANGER |
human CAL-27 cell |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-27 cell growth in a cell viability assay, IC50=44.0054 μM |
SANGER |
human BB49-HNC cell |
Growth inhibition assay |
|
|
|
Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=44.0278 μM |
SANGER |